Clinical Trial Update: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating XXB750 in patients with resistant hypertension has completed, with results reporting on efficacy, safety, tolerability, and dose find…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Resistant Hypertension

Drugs mentioned

• XXB750

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Resistant Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2025-10-24